These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 2437283)

  • 1. Roles of endogenous cholecystokinin in biliary, pancreatic and gastric function: studies with L-364,718, a specific cholecystokinin receptor antagonist.
    Pendleton RG; Bendesky RJ; Schaffer L; Nolan TE; Gould RJ; Clineschmidt BV
    J Pharmacol Exp Ther; 1987 Apr; 241(1):110-6. PubMed ID: 2437283
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacological profile of a new serine derivative cholecystokinin receptor antagonist TP-680 on pancreatic, biliary and gastric function.
    Tachibana I; Kanagawa K; Yamamoto Y; Otsuki M
    J Pharmacol Exp Ther; 1996 Dec; 279(3):1404-12. PubMed ID: 8968365
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term blockade of cholecystokinin (CCK): effects of L 364,718 (a CCK receptor antagonist) on pancreatic enzyme storage and secretion.
    Rodriguez AI; Manso MA; Garcia-Montero AC; Orfao A; de Dios I
    Pancreas; 1997 Oct; 15(3):314-22. PubMed ID: 9336798
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vivo pharmacology of L-364,718, a new potent nonpeptide peripheral cholecystokinin antagonist.
    Lotti VJ; Pendleton RG; Gould RJ; Hanson HM; Chang RS; Clineschmidt BV
    J Pharmacol Exp Ther; 1987 Apr; 241(1):103-9. PubMed ID: 2437282
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of a cholecystokinin receptor antagonist on intestinal phase of pancreatic and biliary responses in man.
    Hildebrand P; Beglinger C; Gyr K; Jansen JB; Rovati LC; Zuercher M; Lamers CB; Setnikar I; Stalder GA
    J Clin Invest; 1990 Mar; 85(3):640-6. PubMed ID: 2312719
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of loxiglumide on pancreatic exocrine secretion stimulated by cholecystokinin-8 in conscious dogs.
    Ninomiya K; Saito T; Wakatsuki K; Saeki M; Kato T; Kasai H; Kimura K; Fujii M
    Arzneimittelforschung; 1998 Jan; 48(1):52-4. PubMed ID: 9522032
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Exocrine effects of the CCK antagonist L-364,718 in canine pancreatic autografts.
    Garvin PJ; Niehoff ML; Burton FR; Dysarz FA; Meadow R; Solomon H
    J Surg Res; 1996 Feb; 61(1):256-9. PubMed ID: 8769975
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Postprandial normal saline intake delays gastric emptying of solids in conscious dogs: partial involvement of CCK in its mechanism.
    Tanaka T; Mizumoto A; Muramatsu S; Mochiki E; Haga N; Suzuki H; Itoh Z
    Dig Dis Sci; 1999 Aug; 44(8):1516-24. PubMed ID: 10492127
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Different actions of CCK on pancreatic and gastric growth in the rat: effect of CCK(A) receptor blockade.
    Varga G; Kisfalvi K; Pelosini I; D'Amato M; Scarpignato C
    Br J Pharmacol; 1998 Jun; 124(3):435-40. PubMed ID: 9647465
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modulation of pancreatic enzyme secretion by melatonin and its precursor; L-tryptophan. Role of CCK and afferent nerves.
    Leja-Szpak A; Jaworek J; Nawrot-Porabka K; Palonek M; Mitis-Musioł M; Dembiński A; Konturek SJ; Pawlik WW
    J Physiol Pharmacol; 2004 Jul; 55 Suppl 2():33-46. PubMed ID: 15608359
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of loxiglumide on pancreatic exocrine secretion stimulated by meal in conscious dogs.
    Ninomiya K; Saito T; Wakatsuki K; Saeki M; Kato T; Edano K; Kasai H; Kimura K; Fujii M
    Arzneimittelforschung; 1998 Jan; 48(1):55-7. PubMed ID: 9522033
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Feedback control of pancreatic secretion in rats. Role of gastric acid secretion.
    Bilski J; Konturek PK; Krzyzek E; Konturek SJ
    J Physiol Pharmacol; 1992 Sep; 43(3):237-57. PubMed ID: 1493255
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of the cholecystokinin receptor antagonist MK-329 on meal-stimulated pancreaticobiliary output in humans.
    Cantor P; Mortensen PE; Myhre J; Gjorup I; Worning H; Stahl E; Survill TT
    Gastroenterology; 1992 May; 102(5):1742-51. PubMed ID: 1568584
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of gastric emptying is a physiological action of cholecystokinin.
    Debas HT; Farooq O; Grossman MI
    Gastroenterology; 1975 May; 68(5 Pt 1):1211-7. PubMed ID: 1126597
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dose-response for inhibition by amylin of cholecystokinin-stimulated secretion of amylase and lipase in rats.
    Young AA; Jodka C; Pittner R; Parkes D; Gedulin BR
    Regul Pept; 2005 Aug; 130(1-2):19-26. PubMed ID: 15982756
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Integrated actions of cholecystokinin on the gastrointestinal tract: use of the cholecystokinin bioassay.
    Liddle RA
    Gastroenterol Clin North Am; 1989 Dec; 18(4):735-56. PubMed ID: 2482253
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of H2-receptor antagonists upon physiological acid secretory states in animals.
    Pendleton RG; Cook PG; Shepherd-Rose A; Mangel AW
    J Pharmacol Exp Ther; 1985 Apr; 233(1):64-9. PubMed ID: 2858583
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of cholecystokinin in postprandial and vagally stimulated duodenal and gallbladder motility in dogs.
    Thor P; Laskiewcz J; Maczka M; Konturek SJ
    J Physiol Pharmacol; 1991 Dec; 42(4):381-8. PubMed ID: 1824297
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cholecystokinin in the control of gastric acid and plasma gastrin and somatostatin secretion in healthy subjects and duodenal ulcer patients before and after eradication of Helicobacter pylori.
    Konturek JW
    J Physiol Pharmacol; 1994 Dec; 45(4 Suppl 1):3-66. PubMed ID: 7787215
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antagonism of receptors for gastrin, cholecystokinin and GRP/bombesin in postprandial stimulation of exocrine pancreas in dogs.
    Konturek SJ; Tasler J; Bilski J; Cieszkowski M; Cai RZ; Schally AV
    J Physiol Pharmacol; 1993 Mar; 44(1):43-53. PubMed ID: 8390873
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.